查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813857

肺癌诊断市场规模、份额和趋势分析报告：按类型、测试、最终用途、地区和细分市场预测，2025-2033 年

Lung Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test (CA Tests, HER2 Tests, ALK Tests), By End Use, Region And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肺癌诊断市场摘要

预计 2024 年全球肺癌诊断市场价值将达到 123.7 亿美元，到 2033 年将达到 233.1 亿美元，2025 年至 2033 年的复合年增长率为 7.5%。

该市场包括旨在促进肺癌早期发现和准确分类的诊断技术。

各种诊断方法，包括影像技术、分子检测和基于切片检查的评估，都被用于支持临床决策。人们越来越重视识别可用于个人化医疗和标靶治疗的基因变异，这推动了先进分子诊断和液态切片方法的应用。

人们日益意识到早期癌症检测的重要性，诊断影像系统和次世代定序仪平台的不断发展，这些因素正在塑造市场格局。基于人工智慧的影像分析的整合以及就地检验解决方案的扩展，也提高了诊断准确性并缩短了周转时间。此外，筛检项目的增加（尤其是在高风险族群中），以及卫生当局的支持性倡议，正在加速对创新诊断工具的需求。这些因素正在推动全球肺癌诊断产业的成长。

在全球范围内，肺癌是男性第二大常见癌症。然而，在一些国家，肺癌是癌症相关死亡的重要原因。常见症状包括咳血、咳嗽以及体重减轻、食慾不振等全身性症状，这些症状会增加包括癌症在内的慢性疾病的可能性。世界卫生组织估计，肺癌每年导致约180万人死亡。男性过度吸烟现象十分普遍，烟草中含有约7,000种化学物质，其中50多种已知会致癌。因此，过量吸烟和吸烟可能是肺癌筛检和诊断的重要因素。

近年来，无论是否吸烟，慢性肺癌患者的数量都显着增加。例如，小细胞肺癌 (SCLC) 患者可能曾经吸烟，也可能从未吸烟。然而，15% 至 20% 的患者曾接触过二手烟或被动吸烟。除了吸烟之外，氡暴露、石棉、遗传、空气污染和饮食因素也会导致患者罹患慢性肺癌。遗传和石棉会增加患者罹患癌症的可能性。

整体而言，全球肺癌诊断产业正朝着更精准、更快速、侵入性更低的方向发展。人工智慧、NGS 和液态切片解决方案的持续整合正在简化临床工作流程，并实现更早的检测，这对于改善患者预后至关重要。对创新技术的投资不断增加以及筛检倡议的不断扩展，预计将进一步增强整个医疗保健系统的诊断能力。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素
    • 肺癌发生率上升
    • 生物标记和分子检测的采用率不断提高
    • 影像和液态生物检体的技术进步
  • 市场限制因素分析
    • 进阶诊断测试高成本
    • 新兴国家的基础建设限制
  • 商业环境分析
    • 依因素（政治/法律、经济/技术）进行 SWOT 分析
    • 波特五力分析
    • COVID-19影响分析

第四章 业务类型分析

  • 肺癌诊断市场：类型变异分析
  • 非小细胞肺癌
  • 小细胞肺癌

第五章 透过测试进行业务分析

  • 肺癌诊断市场：测试波动分析
  • CA 检查
  • HER2检测
  • ALK侦测
  • 血管新生抑制剂
  • EGFR突变检测
  • KRAS突变检测

第六章 以最终用途分類的业务分析

  • 肺癌诊断市场：最终用途差异分析
  • 医院
  • 研究所
  • 其他的

第七章 区域业务分析

  • 2023年及2033年肺癌诊断市占率（按地区）
  • 北美洲
    • 2021-2033年北美肺癌诊断市场
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2021-2033年欧洲肺癌诊断市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2021-2033年亚太地区肺癌诊断市场
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲肺癌诊断市场，2021-2033年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲肺癌诊断市场，2021-2033年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 参与企业概况
  • 财务表现
  • 参与企业
    • 市场领导者
    • 肺癌诊断市场占有率分析（2023年）
    • 公司简介
    • 战略地图
Product Code: 978-1-68038-888-6

Lung Cancer Diagnostics Market Summary

The global lung cancer diagnostics market size was estimated at USD 12.37 billion in 2024 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The market encompasses diagnostic technologies designed to facilitate the early detection and accurate classification of lung cancer, which remains one of the leading causes of cancer-related mortality worldwide.

A broad range of diagnostic modalities, such as imaging techniques, molecular tests, and biopsy-based assessments, are employed to support clinical decision-making. The adoption of advanced molecular diagnostics and liquid biopsy methods is gaining traction, driven by the rising focus on personalized medicine and the identification of actionable genetic mutations for targeted therapy.

Growing awareness about the importance of early cancer detection, coupled with ongoing developments in imaging systems and next-generation sequencing platforms, is shaping the market landscape. The integration of AI-based image analysis and the expansion of point-of-care testing solutions are also improving diagnostic accuracy and reducing turnaround times. In addition, increased screening programs, particularly in high-risk populations, and supportive initiatives by health authorities are accelerating the demand for innovative diagnostic tools. These factors contribute to the growth of the global lung cancer diagnostics industry.

Worldwide, lung cancer is the second leading and most occurring cancer in men. However, in several countries, lung cancer has become one of the prominent causes of cancer-related deaths. The common symptoms include hemoptysis, cough, or systemic symptoms such as weight loss or anorexia that increase the chances of developing chronic conditions, including cancer. The WHO estimates around 1.80 million deaths due to lung cancer worldwide annually. Excessive smoking habits are highly prevalent in men, and tobacco exposure contains around 7,000 chemicals, with more than 50 known cancer-causing chemicals. Therefore, excessive tobacco consumption and smoking are likely to be significant factors for lung screening and diagnostics.

Over the past few years, there has been a prominent rise in patients with chronic lung cancers irrespective of smoking. For instance, patients with small-cell lung cancer (SCLC) may or may not have a smoking history. However, 15 to 20 percent of patients are exposed to secondhand or passive smoking. Besides smoking, other factors such as radon exposure, asbestos, genetics, air pollution, and dietary factors develop chronic conditions in patients. Genetics and asbestos account for a high probability of developing cancerous conditions in patients.

Overall, the global lung cancer diagnostics industry is progressing toward more precise, faster, and less invasive diagnostic approaches. Continuous integration of AI, NGS, and liquid biopsy solutions is streamlining clinical workflows and enabling early detection, which is essential for improving patient outcomes. Growing investments in innovative technologies and the expansion of screening initiatives are expected to further strengthen diagnostic capabilities across healthcare systems.

Global Lung Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the lung cancer diagnostics market report based on type, test, end use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Non-small cell lung cancer
  • Small cell lung cancer
  • Test Outlook (Revenue, USD Million, 2021 - 2033)
  • CA test
  • HER2 test
  • ALK test
  • Angiogenesis Inhibitors
  • EGFR Mutation test
  • KRAS Mutation test
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Lung Cancer Incidence
    • 3.4.2. Growing Adoption of Biomarker and Molecular Testing
    • 3.4.3. Technological Advancements in Imaging and Liquid Biopsy
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost of Advanced Diagnostic Tests
    • 3.5.2. Limited Infrastructure in Emerging Economies
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Lung Cancer Diagnostics Market: Type Movement Analysis
  • 4.2. Non-small Cell Lung Cancer
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Small Cell Lung Cancer
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Test Business Analysis

  • 5.1. Lung Cancer Diagnostics Market: Test Movement Analysis
  • 5.2. CA Test
    • 5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. HER2 Test
    • 5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. ALK Test
    • 5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Angiogenesis Inhibitors
    • 5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. EGFR Mutation test
    • 5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. KRAS Mutation test
    • 5.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. Lung Cancer Diagnostics Market: End Use Movement Analysis
  • 6.2. Hospitals
    • 6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Laboratories
    • 6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Others
    • 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Lung Cancer Diagnostics Market Share By Region, 2023 & 2033
  • 7.2. North America
    • 7.2.1. North America Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target Disease Prevalence
      • 7.2.4.3. Competitive Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Reimbursement Scenario
      • 7.2.4.6. Mexico Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. UK Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Argentina Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's overview
  • 8.2. Financial performance
  • 8.3. Participant categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Lung Cancer Diagnostics Market Share Analysis, 2023
    • 8.3.3. Company Profiles
      • 8.3.3.1. F. Hoffmann-La Roche Ltd
        • 8.3.3.1.1. Company Overview
        • 8.3.3.1.2. Financial Performance
        • 8.3.3.1.3. Product Benchmarking
        • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. Thermo Fisher Scientific
        • 8.3.3.2.1. Company Overview
        • 8.3.3.2.2. Financial Performance
        • 8.3.3.2.3. Product Benchmarking
        • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Illumina Inc.
        • 8.3.3.3.1. Company Overview
        • 8.3.3.3.2. Financial Performance
        • 8.3.3.3.3. Product Benchmarking
        • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Agilent Technologies
        • 8.3.3.4.1. Company Overview
        • 8.3.3.4.2. Financial Performance
        • 8.3.3.4.3. Product Benchmarking
        • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. QIAGEN
        • 8.3.3.5.1. Company Overview
        • 8.3.3.5.2. Financial Performance
        • 8.3.3.5.3. Product Benchmarking
        • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. Abbott
        • 8.3.3.6.1. Company Overview
        • 8.3.3.6.2. Financial Performance
        • 8.3.3.6.3. Product Benchmarking
        • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Bio-Rad
        • 8.3.3.7.1. Company Overview
        • 8.3.3.7.2. Financial Performance
        • 8.3.3.7.3. Product Benchmarking
        • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Neogenomics Laboratories
        • 8.3.3.8.1. Company Overview
        • 8.3.3.8.2. Financial Performance
        • 8.3.3.8.3. Product Benchmarking
        • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. bioMerieux
        • 8.3.3.9.1. Company Overview
        • 8.3.3.9.2. Financial Performance
        • 8.3.3.9.3. Product Benchmarking
        • 8.3.3.9.4. Strategic Initiatives
      • 8.3.3.10. Myriad Genetics, Inc.
        • 8.3.3.10.1. Company Overview
        • 8.3.3.10.2. Financial Performance
        • 8.3.3.10.3. Product Benchmarking
        • 8.3.3.10.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others

List of Tables

  • TABLE 1 Lung Cancer Diagnostics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
  • TABLE 2 Global Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 3 Global Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 4 Global Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 5 Global Lung Cancer Diagnostics Market, by region, 2021 - 2033 (USD Million)
  • TABLE 6 Lung Cancer Diagnostics- Key market driver analysis
  • TABLE 7 Lung Cancer Diagnostics- Key market restraint analysis
  • TABLE 8 North America Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 9 North America Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 10 North America Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 11 North America Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 12 U.S. Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 13 U.S. Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 14 U.S. Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 15 Canada Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 16 Canada Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 17 Canada Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 18 Mexico Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 19 Mexico Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 20 Mexico Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 21 Europe Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 22 Europe Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 23 Europe Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 24 Europe Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 25 Germany Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 26 Germany Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 27 Germany Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 28 UK Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 29 UK Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 30 UK Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 31 France Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 32 France Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 33 France Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 34 Italy Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 35 Italy Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 36 Italy Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 37 Spain Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 38 Spain Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 39 Spain Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 40 Denmark Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 41 Denmark Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 42 Denmark Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 43 Sweden Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 44 Sweden Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 45 Sweden Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 46 Norway Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 47 Norway Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 48 Norway Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 49 Asia Pacific Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 50 Asia Pacific Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 51 Asia Pacific Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 52 Asia Pacific Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 53 Japan Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 54 Japan Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 55 Japan Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 56 China Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 57 China Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 58 China Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 59 India Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 60 India Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 61 India Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 62 Australia Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 63 Australia Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 64 Australia Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 65 South Korea Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 66 South Korea Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 67 South Korea Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 68 Thailand Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 69 Thailand Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 70 Thailand Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 71 Latin America Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 72 Latin America Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 73 Latin America Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 74 Latin America Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 75 Brazil Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 76 Brazil Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 77 Brazil Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 78 Argentina Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 79 Argentina Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 80 Argentina Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 81 MEA Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 82 MEA Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 83 MEA Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 84 MEA Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 85 South Africa Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 86 South Africa Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 87 South Africa Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 88 Saudi Arabia Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 89 Saudi Arabia Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 90 Saudi Arabia Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 91 UAE Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 92 UAE Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 93 UAE Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 94 Kuwait Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 95 Kuwait Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 96 Kuwait Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • FIG. 1 Lung Cancer Diagnostics Market Segmentation
  • FIG. 2 Global Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 3 Lung Cancer Diagnostics Market Dynamics
  • FIG. 4 Key Opportunities Prioritized, 2018
  • FIG. 5 Lung Cancer Diagnostics Market - Porter's Analysis
  • FIG. 6 Lung Cancer Diagnostics Market - PESTEL Analysis
  • FIG. 7 Lung Cancer Diagnostics Revenue Share, By Type, 2023 & 2033
  • FIG. 8 Non-small cell lung cancer Market, 2021 - 2033 (USD Million)
  • FIG. 9 Small cell lung cancer Market, 2021 - 2033 (USD Million)
  • FIG. 10 Lung Cancer Diagnostics Revenue Share, By Test, 2023 & 2033
  • FIG. 11 CA test Market, 2021 - 2033 (USD Million)
  • FIG. 12 HER2 test Market, 2021 - 2033 (USD Million)
  • FIG. 13 ALK test Market, 2021 - 2033 (USD Million)
  • FIG. 14 Angiogenesis Inhibitors Market, 2021 - 2033 (USD Million)
  • FIG. 15 EGFR Mutation Test Market, 2021 - 2033 (USD Million)
  • FIG. 16 KRAS Mutation Test Market, 2021 - 2033 (USD Million)
  • FIG. 17 Lung Cancer Diagnostics Revenue Share, By End Use, 2023 & 2033
  • FIG. 18 Hospitals Market, 2021 - 2033 (USD Million)
  • FIG. 19 Laboratories Market, 2021 - 2033 (USD Million)
  • FIG. 20 Others Market, 2021 - 2033 (USD Million)
  • FIG. 21 Lung Cancer Diagnostics Revenue Share, By Region, 2023 & 2033
  • FIG. 22 North America Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 23 U.S. Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 24 Canada Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 25 Mexico Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 26 Europe Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 27 Germany Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 28 UK Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 29 France Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 30 Italy Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 31 Spain Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 32 Denmark Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 33 Sweden Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 34 Norway Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 35 Asia Pacific Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 36 Japan Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 37 China Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 38 India Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 39 Australia Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 40 South Korea Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 41 Thailand Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 42 Latin America Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 43 Brazil Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 44 Argentina Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 45 MEA Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 46 South Africa Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 47 Saudi Arabia Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 48 UAE Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 49 Kuwait Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)